Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.

Chambers SK, Chow HH, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Abu Shahin N, Alberts DS.

Clin Cancer Res. 2012 May 1;18(9):2668-78. doi: 10.1158/1078-0432.CCR-12-0261. Epub 2012 Mar 15.

2.

Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.

Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF.

Gynecol Oncol. 2011 Dec;123(3):479-85. doi: 10.1016/j.ygyno.2011.08.018. Epub 2011 Oct 5.

PMID:
21978765
3.

Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer.

Hess LM, Chambers SK, Hatch K, Hallum A, Janicek MF, Buscema J, Borst M, Johnson C, Slayton L, Chongpison Y, Alberts DS.

J Support Oncol. 2010 Nov-Dec;8(6):252-8.

PMID:
21265392
4.

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS.

Clin Cancer Res. 2010 Nov 1;16(21):5320-8. doi: 10.1158/1078-0432.CCR-10-0974.

5.

Cervical cancer: prevention, diagnosis, and therapeutics.

Janicek MF, Averette HE.

CA Cancer J Clin. 2001 Mar-Apr;51(2):92-114; quiz 115-8. Review.

6.

Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.

Schoell WM, Mirhashemi R, Liu B, Janicek MF, Podack ER, Penalver MA, Averette HE.

Gynecol Oncol. 1999 Sep;74(3):448-55.

PMID:
10479508
7.

Critical care issues in cervical cancer management.

Mirhashemi R, Janicek MF, Schoell WM.

Semin Surg Oncol. 1999 Apr-May;16(3):267-74. Review.

PMID:
10225307
8.

Epidemiology and biology of cervical cancer.

Schoell WM, Janicek MF, Mirhashemi R.

Semin Surg Oncol. 1999 Apr-May;16(3):203-11. Review.

PMID:
10225296
9.

p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.

Janicek MF, Angioli R, Unal AD, Sevin BU, Madrigal M, Estape R, Averette HE.

Gynecol Oncol. 1997 Jul;66(1):94-102.

PMID:
9234928
10.

In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.

Madrigal M, Janicek MF, Sevin BU, Perras J, Estape R, PeƱalver M, Averette HE.

Gynecol Oncol. 1997 Jan;64(1):18-25.

PMID:
8995542
11.

Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines.

Janicek MF, Sevin BU, Nguyen HN, Averette HE.

Gynecol Oncol. 1995 Oct;59(1):87-92.

PMID:
7557622
12.
13.

Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia.

Janicek MF, Rosenshein NB.

Gynecol Oncol. 1994 Mar;52(3):373-8.

PMID:
8157194
14.

Malondialdehyde precursors in gamma-irradiated DNA, deoxynucleotides and deoxynucleosides.

Janicek MF, Haseltine WA, Henner WD.

Nucleic Acids Res. 1985 Dec 20;13(24):9011-29.

Supplemental Content

Loading ...
Support Center